APOC3 and atherosclerosis: The ANGTPL3 monoclonal antibody inhibitor evinacumab has been shown to reduce levels of LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and apolipoprotein CIII (ApoCIII), all known contributors of risk for ASCVD [11, 12].